Working Group Members
Marina Binotto
GlaxoSmithKline
Denise Cloutier
Pfizer
David Cotes
Johnson & Johnson
Denis Drolet
Merck Frosst
Gilles Gagnon
Prodevpharma
Michèle Houppert
MDEIE
Jean Lachaine
Université de Montréal
Yves Lacoursière
sanofi-aventis
Jean-Frédérique Lafontaine
AstraZeneca
Hélène Larouche
Wyeth
Michel Rousseau
Novartis
Pierre Vanier
DEC
Claude Warren
Johnson & Johnson
Mise à jour : 11 mars 2009
Working groups
The Commercialization Working Group
Mission
Encourage the development of a healthy local, regional and national business environment, suitable for investment and wealth creation;
Montréal InVivo’s role will be to highlight the impact of the solutions proposed by this working group upon the economic health of the entire life sciences and health technologies industry and, more specifically, upon our health.
Challenges
Complexity and inertia of the regulatory and legislative environment;
Lack of understanding of the socio-economic potential of the health industry;
Difficulty of access to the Quebec market;
Absence of a functioning network that brings together big pharma and the other actors in the cluster.
Projects
Source : Bilan des activités de Montréal InVivo pour la période du 1er janvier au 31 décembre 2007 (Summary of activities of Montréal InVivo for the period January 1 to December 31 2007)
Consultez notre groupe du LinkedIn